Speaker illustration

Professor Gilles Montalescot

Sorbonne University, Paris (France)

Gilles Montalescot is Professor of Cardiology at the Pitié-Salpêtrière Hospital in Paris, France, where he heads the Department of Cardiology at the Institute of Cardiology. He is a practicing Interventional Cardiologist and has extensive experience in basic and clinical research. He has been the director of the INSERM research Unit UMRS_1166 on Thrombosis for 10 years. Dr Montalescot has been an investigator for many of the new drugs developed in the past twenty years as well as for many of the new interventional technologies. Dr. Montalescot is a senior scientist and has been the lead investigator of many national or international randomized trials including ADMIRAL, ARMADA, ALBION, STEEPLE, ARCHIPELAGO, ABOARD, ACAPULCO, ATOLL, ARCTIC, ANTARCTIC, ACCOAST, ATLANTIC, AEGEAN, AMERICA, ALBATROS, ATLANTIS, ALPHEUS, ARAMIS, ADRIFT, AMUNDSEN trials. Dr Montalescot is the Chairman of the ACTION study group, an Academic Research Organization based at Pitié-Salpêtrière Hospital in Paris.

LDL Management in ACS: Lower is better but is Earlier better?

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Prevention

Session type: Industry Live

Thumbnail

First clinical experience with a smart textile

Event: ESC CONGRESS 2019

Topic: Hospital Information Systems, Electronic Medical Records, Clinical Decision Support

Session type: Practical Tutorials

Thumbnail

Vascular protection: when do patients need more?

Event: ESC CONGRESS 2019

Topic: Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

Mechanisms behind intrinsic myocardial repair and regeneration

Event: ESC CONGRESS 2019

Topic: Stem Cells, Cell Cycle, Cell Senescence, Cell Death

Session type: Symposium

Thumbnail

Vascular protection - Which of your patients with chronic coronary artery disease will benefit?

Event: ESC CONGRESS 2019

Topic: Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)

Session type: Satellite Symposium

Thumbnail

From trial to treatment in vascular protection: which high risk CAD/PAD patients benefit the most?

Event: ESC CONGRESS 2019

Topic: Treatment

Session type: Practical Tutorials

Thumbnail

Non-vitamin K antagonist oral anticoagulants (NOACs): from new evidence to improved patient outcomes in atrial fibrillation

Event: ESC CONGRESS 2019

Topic: Atrial Fibrillation (AF)

Session type: Satellite Symposium

Thumbnail

Oral P2Y12 inhibitors in acute coronary syndromes: are they all equal?

Event: ESC Congress 2018

Topic: Pharmacotherapy

Session type: Rapid Fire Abstracts

Thumbnail

State of the art in platelet biology

Event: ESC CONGRESS 2017

Topic: Platelets

Session type: Advances in Science

Thumbnail

Overcoming the dilemma of stroke versus bleeding in non-valvular atrial fibrillation: can we optimise patient care with oral factor Xa inhibition

Event: ESC CONGRESS 2014

Topic: Atrial fibrillation (AF)

Session type: Satellite Symposium

Thumbnail

This platform is supported by

logo Novo Nordisk